{
Fresenius SE & Co. KGaA

Companies

}
001122334455554433221100
001122334455554433221100

fresenius maintains strong performance with q1 results and top pick status

Deutsche Bank has reaffirmed its 'Top Pick' status for Fresenius SE & Co. KGaA following a strong Q1 performance. The company specializes in medical drugs and equipment, with 64.3% of net sales from hospital administration and engineering, and 35.7% from perfusion and clinical nutrition. Geographically, 72.4% of sales are generated in Europe, followed by North America (12.3%), Asia/Pacific (7.3%), Latin America (6.4%), and Africa (1.6%).
MarketScreener
Fresenius SE & Co. KGaA DEU ZAF USA BRA AUS Show more
Business & Industry, Market Report
09:42 08.05.2025

ubs raises fresenius price target to 47 euros maintains buy rating

UBS has increased its price target for Fresenius from 40 to 47 euros while maintaining a "Buy" rating. Analyst Graham Doyle emphasized that the company's focus is shifting towards value creation rather than merely avoiding losses, and he believes that current market expectations are overly pessimistic regarding the biosimilars sector.
boerse.de
Euro Fresenius SE & Co. KGaA DEU Graham Doyle
Finance & Economy, Market Report
07:21 26.03.2025

ubs raises fresenius target price to 47 euros maintains buy rating

UBS has increased its target price for Fresenius SE from 40 to 47 euros while maintaining a "Buy" rating. Analyst Graham Doyle emphasized that the company's focus is shifting towards value creation rather than merely avoiding losses, and he believes that current market expectations are overly pessimistic, particularly regarding the biosimilars sector.
MarketScreener
Euro Fresenius SE & Co. KGaA DEU CHE Graham Doyle
Finance & Economy, Market Report
07:08 26.03.2025

ubs upgrades fresenius se to buy with target price of 40 euros

UBS AG has upgraded Fresenius SE to "Buy" with a target price of 40 euros, following a review that noted the company's recent sales and adjusted operating profit exceeded expectations. Despite a conservative outlook for 2025, the positive reception is bolstered by Kabi's success and raised medium-term targets. As of midday trading, Fresenius shares rose by 7.9% to EUR 39.45, indicating further upside potential.
finanzen.net
Euro Fresenius SE & Co. KGaA UBS AG DEU CHE Graham Doyle
Finance & Economy, Market Report
13:26 26.02.2025

Fresenius reports strong performance with positive outlook from UBS analysis

Fresenius SE & Co. KGaA, a leader in medical products and services, reports strong performance with net sales primarily from hospital administration (64.3%) and clinical nutrition (35.7%). Geographically, the majority of sales come from Europe (72.4%), followed by North America (12.3%) and Asia/Pacific (7.3%).
MarketScreener
United States Dollar Fresenius SE & Co. KGaA DEU Show more
Business & Industry, Market Report
10:09 26.02.2025

fresenius reports strong performance in medical equipment and nutrition sectors

Fresenius SE & Co. KGaA, a leader in medical drugs and equipment, reports strong performance with net sales primarily from hospital administration (64.3%) and clinical nutrition (35.7%). Geographically, 72.4% of sales come from Europe, followed by North America (12.3%) and Asia/Pacific (7.3%).
MarketScreener
Euro Fresenius SE & Co. KGaA DEU
Business & Industry, Market Report
09:52 26.02.2025

ubs rates fresenius se shares as buy with target price of 40 euros

UBS AG has maintained a "Buy" rating for Fresenius SE shares, setting a target price of 40 euros. Despite US investors showing indifference towards European medical technology manufacturers, Fresenius shares have gained 1.2% to EUR 37.99, reflecting a 5.29% upside potential. The company is expected to release its Q4 2024 results on March 26, 2025.
finanzen.net
Euro UBS AG Fresenius SE & Co. KGaA DEU USA Graham Doyle
Finance & Economy, Market Report
18:58 11.02.2025

ubs maintains buy rating for fresenius with target price of 40 euros

UBS has maintained a 'Buy' rating for Fresenius SE, setting a target price of 40 euros. Analyst Graham Doyle noted that US investors show indifference towards European medical technology manufacturers, with Fresenius shares currently valued higher than their US counterparts amid potential import duties.
MarketScreener
Euro SIEMENS HEALTHINEERS Fresenius SE & Co. KGaA CHE USA DEU Graham Doyle Show more
Business & Industry, Market Report
11:10 11.02.2025

ubs maintains buy rating for fresenius with target price of 40 euros

UBS has maintained a "Buy" rating for Fresenius SE, setting a target price of 40 euros. Analyst Graham Doyle emphasized the need for the company to address challenges posed by Helios 2025 during the upcoming reporting season for the European medical technology sector.
boerse.de
Euro Fresenius SE & Co. KGaA DEU Graham Doyle Thomas Müller
Finance & Economy, Market Report
13:33 31.01.2025

UBS maintains buy rating for Fresenius with target price of 40 euros

UBS has maintained a 'Buy' rating for Fresenius SE, setting a target price of 40 euros. Analyst Graham Doyle highlighted the company's need to address challenges posed by Helios 2025 during the European medical technology sector's reporting season.
boerse.de
Euro Fresenius SE & Co. KGaA DEU CHE Graham Doyle Thomas Müller
Finance & Economy, Market Report
11:11 31.01.2025
Trending
Subcategory
AI Innovations Corporate News Stock Market Updates Industry Trends Market Analysis and Predictions Startups & Entrepreneurship Banking Regulations Emerging Startups Cybersecurity Innovations & Tech Funding Rounds & Investments Product Launches Economic Indicators Fintech Startups Private Equity Deals Software Development Trends Venture Capital Investments Retail and Consumer Goods Industry Mergers & Acquisitions AI Applications Finance Mergers & Acquisitions
Countries:
USA CHN CHE IND ARE GBR FRA DEU JPN SAU KOR VNM SGP IDN RUS ISR PHL AUS EGY QAT
Companies:
Huawei Technologies CO. Ltd. UBS Group AG NVIDIA Corporation Nvidia Corporation Apple Inc. Google Inc. Microsoft Corporation Corp. Berner Kantonalbank AG Deutsche Bank AG Crane Company Deyaar Development PJSC Maverick Ventures (Israel) 1.5 GP Ltd. SuperSeed B.V. DeepSeek R1 USD Tencent Holdings Limited XPeng Inc. Toyota Motor Corporation Alphabet Inc. Xiaomi Corporation NEO-NEON
Currencies:
United States Dollar Euro Chinese Yuan Swiss Franc Indian Rupee British Pound Sterling Japanese Yen South African Rand Filipino Peso Norwegian Krone Offshore Chinese Yuan
People:
Ren Zhengfei Jensen Huang Donald Trump Howard Lutnick Scott Bessent Oded Shmueli Ben Luria Michael Leybovich Xi Jinping Karim Jouini Jihed Othmani Iheb Triki Mohamed Ali Abid Roxanne Varza Guillaume Amblard Andreas Venditti Mohamed Alabbar Saeed Mohammed Al Qatami Khaled Al Huraimel Renzo Piano

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.